An evidence-based algorithm for the use of B-type natriuretic testing in acute coronary syndromes

Reviews in Cardiovascular Medicine

Volumn 11, Issue SUPPL. 2, 2010, Pages

  McCullough, Peter A ^a   Peacock, W Frank ^b   O'Neil, Brian ^c   De Lemos, James A ^d   Lepor, Norman E ^e   Berkowitz, Robert ^f  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^e CEDARS SINAI MEDICAL CENTER   (United States)

^f HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Acute coronary syndrome; Acute myocardial infarction; B type natriuretic peptide; Complications; Diagnosis; Hospitalization; Mortality; N terminal pro B type natriuretic peptide; Prognosis; Systematic review

Indexed keywords

ADRENOMEDULLIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CYCLIC GMP; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; INTERLEUKIN 6; MEMBRANE METALLOENDOPEPTIDASE; MEPRIN; MYOGLOBIN; NATRIURETIC FACTOR; NORADRENALIN; ORBOFIBAN; RANOLAZINE; SIMVASTATIN; TENECTEPLASE; THROMBOCYTE RECEPTOR; TIROFIBAN; BIOLOGICAL MARKER; PEPTIDE FRAGMENT; PRO BRAIN NATRIURETIC PEPTIDE (1 76); PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ACUTE CORONARY SYNDROME; AGING; ALGORITHM; ANGINA PECTORIS; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOGENIC SHOCK; CARDIOVASCULAR RISK; CHROMOSOME 1; CONSERVATIVE TREATMENT; CORONARY ARTERY DISEASE; DEFIBRILLATOR; DIABETES MELLITUS; DISEASE CLASSIFICATION; ELECTROCARDIOGRAPHY; EVIDENCE BASED MEDICINE; FIBRINOLYTIC THERAPY; FOLLOW UP; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE CELL; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE TENSION; HORMONAL REGULATION; HOSPITAL READMISSION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; META ANALYSIS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREDICTIVE VALUE; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; SEX DIFFERENCE; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; UNSTABLE ANGINA PECTORIS; BLOOD; CLINICAL PATHWAY; DYSPNEA; PRACTICE GUIDELINE; PREDICTION AND FORECASTING; RISK ASSESSMENT; RISK FACTOR; UPREGULATION;

ACUTE CORONARY SYNDROME; ALGORITHMS; BIOLOGICAL MARKERS; CHEST PAIN; CRITICAL PATHWAYS; DYSPNEA; EVIDENCE-BASED MEDICINE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; UP-REGULATION;

EID: 77958132374     PISSN: 15306550     EISSN: None     Source Type: Journal    
DOI: 10.3909/ricm11S2S0002     Document Type: Review

References (58)

1. McCullough PA, Nowak RM, McCord J, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation. 2002;106:416-422. (Pubitemid 34803684)
2. Silver MA, Maisel A, Yancy CW, et al; BNP Consensus Panel. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardio-vascular diseases. Congest Heart Fail. 2004;10:1-30.
3. McCullough PA, Neyou A. Comprehensive review of the relative clinical utility of B-type natriuretic peptide and N-terminal pro-B-type natriuretic peptide assays in cardiovascular disease. Open Heart Fail J. 2009;2:6-17.
4. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med. 2001;39:571-588. (Pubitemid 32725741)
5. Liang F, O'Rear J, Schellenberger U, et al. Evidence for functional heterogeneity of circulating B-type natriuretic peptide. J Am Coll Cardiol. 2007;49:1071-1078. (Pubitemid 46349497)
6. Lam CS, Burnett JC Jr, Costello-Boerrigter L, et al. Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. J Am Coll Cardiol. 2007;49:1193-1202. (Pubitemid 46400332)
7. Sabatine MS, Morrow DA, de Lemos JA, et al. Acute changes in circulating natriuretic peptide levels in relation to myocardial ischemia. J Am Coll Cardiol. 2004;44:1988-1995. (Pubitemid 39473283)
8. Goetze JP, Jensen G, Møller S, et al. BNP and N-terminal proBNP are both extracted in the normal kidney. Eur J Clin Invest. 2006;36:8-15.
9. Beleigoli AM, Diniz MF, Ribeiro AL. Natriuretic peptides: linking heart and adipose tissue in obesity and related conditions-a systematic review. Obes Rev. 2009;10:617-626.
10. Costello-Boerrigter LC, Burnett JC Jr. A new role for the natriuretic peptides: metabolic regulators of the adipocyte. J Am Coll Cardiol. 2009;53:2078-2079.
11. Moro C, Berlan M. Cardiovascular and metabolic effects of natriuretic peptides. Fundam Clin Pharmacol. 2006;20:41-49.
12. Galvani M, Ferrini D, Ottani F. Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail. 2004;6:327-333. (Pubitemid 38253053)
13. Morrow DA, Cannon CP, Jesse RL, et al; National Academy of Clinical Biochemistry. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines: clinical characteristics and utilization of biochemical markers in acute coronary syndromes. Clin Chem. 2007;53:552-574. (Pubitemid 46580223)
14. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J Am Coll Cardiol. 2007;50:e1-e157.
15. Ang DS, Wei L, Kao MP, et al. A comparison between B-type natriuretic peptide, Global Registry of Acute Coronary Events (GRACE) score and their combination in ACS risk stratification. Heart. 2009;95:1836-1842.
16. Cameron SJ, Green GB, White CN, et al. Assessment of BNP and NT-proBNP in emergency department patients presenting with suspected acute coronary syndromes. Clin Biochem. 2006;39:11-18. (Pubitemid 43005265)
17. Jernberg T, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol. 2003;42:1909-1916. (Pubitemid 37485564)
18. Omland T, Aakvaag A, Bonarjee W, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963-1969.
19. de Lemos JA, Morrow DA, Bentley JH, et al. The prognostic value of B-Type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med. 2001;345:1014-1021.
20. Windhausen F, Hirsch A, Sanders GT, et al; Invasive versus Conservative Treatment in Unstable coronary Syndromes investigators. N-terminal pro-brain natriuretic peptide for additional risk stratification in patients with non-ST-elevation acute coronary syndrome and an elevated troponin T: an Invasive versus Conservative Treatment in Unstable coronary Syndromes (ICTUS) substudy. Am Heart J. 2007;153:485-492. (Pubitemid 46440676)
21. Jernberg T, Stridsberg M, Venge P, Lindahl B. N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol. 2002;40:437-445. (Pubitemid 34833157)
22. Heeschen C, Hamm CW, Mitrovic V, et al; Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. Circulation. 2004;110:3206-3212. (Pubitemid 39525067)
23. Morrow DA, de Lemos JA, Sabatine MS, et al. Evaluation of B-type natriuretic peptide for risk assessment in unstable angina/non-ST-elevation myocardial infarction. J Am Coll Cardiol. 2003;41:1264-1272.
24. Morrow DA, Scirica BM, Sabatine MS, et al. B-type natriuretic peptide and the effect of ranolazine in patients with non-ST-segment elevation acute coronary syndromes: observations from the MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary- Thrombolysis in Myocardial Infarction 36) trial. J Am Coll Cardiol. 2010;55:1189-1196.
25. Weber M, Hamm C. Role of B-type natriuretic peptide (BNP) and NT-proBNP in clinical routine. Heart. 2006;92:843-849. (Pubitemid 43799232)
26. Omland T, Persson A, Ng L, et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation. 2002;106:2913-2918. (Pubitemid 35424741)
27. Weber M, Bazzino O, Navarro Estrada JL, et al. N-terminal B-type natriuretic peptide assessment provides incremental prognostic information in patients with acute coronary syndromes and normal troponin T values upon admission. J Am Coll Cardiol. 2008;51:1188-1195. (Pubitemid 351382099)
28. Sabatine MS, Morrow DA, de Lemos JA, et al. Multimarker approach to risk stratification in non-ST elevation acute coronary syndromes: simultaneous assessment of troponin I, C-reactive protein, and B-type natriuretic peptide. Circulation. 2002;105:1760-1763. (Pubitemid 34408881)
29. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation. 1998;97:1921-1929.
30. Richards AM, Nicholls MG, Espiner EA, et al. B-type natriuretic peptides and election fraction for prognosis after myocardial infarction. Circulation. 2003;107:2786-2792. (Pubitemid 36705987)
31. Mega JL, Morrow DA, de Lemos JA, et al. B-type natriuretic peptide at presentation and prognosis in patients with ST-segment elevation myocardial infarction: an ENTIRE-TIMI-23 substudy. J Am Coll Cardiol. 2004;44:335-339. (Pubitemid 38950592)
32. Grabowskl M, Filipiak KJ, Karpinski G, et al. Serum B-type natriuretic peptide levels on admission predict not only short-term death but also angiographic success of procedure in patients with acute ST-elevation myocardial infarction treated with primary angioplasty. Am Heart J. 2004;148:655-662. (Pubitemid 39349386)
33. Palazzuoli A, Gennari L, Calabria P, et al. Relation of plasma brain natriuretic peptide levels in non-ST-elevation coronary disease and preserved systolic function to number of narrowed coronary arteries. Am J Cardiol. 2005;96:1705-1710.
34. Staub D, Jonas N, Zellweger Mj, et al. Use of N-terminal pro-B-type natriuretic peptide to detect myocardial ischemia. Am J Med. 2005;118:1287.
35. Neyou A, O'Neil B, Berman AD, et al. Determinants of markedly elevated B-type natriuretic peptide in patients with ST-segment elevation myocardial infarction. Am J Emerg Med. In press.
36. Lindahl B, Lindbäck J, Jernberg T, et al. Serial analyses of N-terminal pro-B-type natriuretic peptide in patients with non-ST-segment elevation acute coronary syndromes: a Fragmin and fast Revascularisation during In Stability in Coronary artery disease (FRISC)-II substudy. J Am Coll Cardiol. 2005;45:533-541. (Pubitemid 40222247)
37. Bhardwaj A, Januzzi JL Jr. Natriuretic peptide-guided management of acutely destabilized heart failure: rationale and treatment algorithm. Crit Pathw Cardiol. 2009;8:146-150.
38. Anwaruddin S, Lloyd-Jones DM, Baggish A, et al. Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRJDE) Study. J Am Coll Cardiol. 2006;47:91-97. (Pubitemid 43005170)
39. Crilley JG, Farrer M. Left ventricular remodelling and brain natriuretic peptide after first myocardial infarction. Heart. 2001;86:638-642. (Pubitemid 33086878)
40. Sadanandan S, Cannon CP, Chekuri K, et al. Association of elevated B-type natriuretic peptide levels with angiographic findings among patients with unstable angina and non-ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2004;44:564-568. (Pubitemid 39078180)
41. Grabowski M, Filipiak KJ, Malek LA, et al. Admission B-type natriuretic peptide assessment improves early risk stratification by Killip classes and TIMI risk score in patients with acute ST elevation myocardial infarction treated with primary angioplasty. Int J Cardiol. 2007;115:386-390. (Pubitemid 46185640)
42. Morrow DA, de Lemos JA, Blazing MA, et al; A to Z Investigators. Prognostic value of serial B-rype natriuretic peptide testing during follow-up of patients with unstable coronary artery disease. JAMA. 2005;294:2866-2871. (Pubitemid 41785867)
43. Kuklinska AM, Sobkowicz B, Mroczko B, et al. Prognostic significance of the admission plasma B-type natriuretic peptide measurement in patients with first ST-elevation myocardial infarction in comparison with C-reactive protein and TIMI risk score. Clin Chim Acta. 2007;382:106-111. (Pubitemid 46782740)
44. Brown AM, Sease KL, Robey JL, et al. The impact of B-type natriuretic peptide in addition to troponin I, creatine kinase-MB, and myoglobin on the risk stratification of emergency department chest pain patients with potential acute coronary syndrome. Ann Emerg Med. 2007;49:153-163. (Pubitemid 46108141)
45. Jeong YH, Lee SW, Lee CW, et al. Biomarkers on admission for the prediction of cardiovascular events after primary stenting in patients with ST-elevation myocardial infarction. Clin Cardiol. 2008;31:572-579.
46. Brügger-Andersen T, Pönitz V, Staines H, et al. B-type natriuretic peptide is a long-term predictor of all-cause mortality, whereas high-sensitive C-reactive protein predicts recurrent short-term troponin T positive cardiac events in chest pain patients: a prognostic study. BMC Cardiovasc Disord. 2008;8:34.
47. Ang DS, Kong CF, Kao MP, Struthers AD. Serial bedside B-type natriuretic peptide strongly predicts prognosis in acute coronary syndrome independent of echocardiographic abnormalities. Am Heart J. 2009;158:133-140.
48. Ang DS, Welsh P, Watt P, et al. Serial changes in adiponectin and BNP in ACS patients: paradoxical associations with each other and with prognosis. Clin Sci (Lond). 2009;117:41-48.
49. James SK, Lindahl B, Siegbahn A, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation. 2003;108:275-281. (Pubitemid 36899016)
50. Zeller M, Cottin Y, Laurent Y, et al. N-terminal pro-brain natriuretic peptide levels in patients with non-ST-elevation myocardial infarction. Cardiology. 2004;102:37-40. (Pubitemid 38490260)
51. Galvani M, Ottani F, Oltrona L, et al; Italian Working Group on Atherosclerosis, Thrombosis, and Vascular Biology and the Associazione Nazionale Medici Cardiologi Ospedalieri (ANMCO). N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation. 2004;110:128-134.
52. Bazzino O, Fuselli JJ, Botto F, et al; PACS Group of Investigators. Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J. 2004;25.859-866.
53. Kim H, Yang DH, Park Y, et al. Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome. Circ J. 2006;70:1379-1384. (Pubitemid 44672891)
54. Kavsak PA, Ko DT, Newman AM, et al. Risk stratification for heart failure and death in an acute coronary syndrome population using Inflammatory cytokines and N-terminal pro-brain natriuretic peptide. Clin Chem. 2007;53:2112-2118. (Pubitemid 350197294)
55. Kavsak PA, Newman AM, Ko DT, et al. Is a pattern of increasing biomarker concentrations important for long-term risk stratification in acute coronary syndrome patients presenting early after the onset of symptoms? Clin Chem. 2008;54:747-751. (Pubitemid 351573717)
56. Hong YJ, Ahn Y, Sim DS, et al. Relation between N-terminal pro-B-type natriuretic peptide and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis. Coron Artery Dis. 2009;20:518-524.
57. Sarullo FM, Gristina T, Brusca I, et al. Usefulness of N-terminal pro-B-type natriuretic peptide levels in predicting residual myocardial ischemia in patients with ST elevation acute myocardial infarction. Minerva Cardioangiol. 2007;55:149-155. (Pubitemid 46762208)
58. Kwon TG, Bae JH, Jeong MH, et al; Korea Acute Myocardial Infarction Registry Investigators. N-terminal pro-B-type natriuretic peptide is associated with adverse short-term clinical outcomes in patients with acute ST-elevation myocardial infarction who underwent primary percutaneous coronary intervention. Int J Cardiol. 2009;133:173-178.